220 related articles for article (PubMed ID: 10896793)
1. The effect of a monoclonal antibody coupled to ricin A chain-derived peptides on endothelial cells in vitro: insights into toxin-mediated vascular damage.
Baluna R; Coleman E; Jones C; Ghetie V; Vitetta ES
Exp Cell Res; 2000 Aug; 258(2):417-24. PubMed ID: 10896793
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy.
Ghetie MA; May RD; Till M; Uhr JW; Ghetie V; Knowles PP; Relf M; Brown A; Wallace PM; Janossy G
Cancer Res; 1988 May; 48(9):2610-7. PubMed ID: 2451562
[TBL] [Abstract][Full Text] [Related]
3. The generation of immunotoxins using chimeric anti-CD22 antibodies containing mutations which alter their serum half-life.
Pop LM; Liu X; Ghetie V; Vitetta ES
Int Immunopharmacol; 2005 Jul; 5(7-8):1279-90. PubMed ID: 15914332
[TBL] [Abstract][Full Text] [Related]
4. Ricin A-chain and ricin A-chain immunotoxins rapidly damage human endothelial cells: implications for vascular leak syndrome.
Soler-Rodríguez AM; Ghetie MA; Oppenheimer-Marks N; Uhr JW; Vitetta ES
Exp Cell Res; 1993 Jun; 206(2):227-34. PubMed ID: 8388800
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemias.
Kreitman RJ; Margulies I; Stetler-Stevenson M; Wang QC; FitzGerald DJ; Pastan I
Clin Cancer Res; 2000 Apr; 6(4):1476-87. PubMed ID: 10778980
[TBL] [Abstract][Full Text] [Related]
6. Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display.
Salvatore G; Beers R; Margulies I; Kreitman RJ; Pastan I
Clin Cancer Res; 2002 Apr; 8(4):995-1002. PubMed ID: 11948105
[TBL] [Abstract][Full Text] [Related]
7. Bispecific anti-CD22/anti-CD3-ricin A chain immunotoxin is cytotoxic to Daudi lymphoma cells but not T cells in vitro and shows both A-chain-mediated and LAK-T-mediated killing.
Shen GL; Li JL; Vitetta ES
J Immunol; 1994 Mar; 152(5):2368-76. PubMed ID: 8133047
[TBL] [Abstract][Full Text] [Related]
8. Immunotoxins constructed with chimeric, short-lived anti-CD22 monoclonal antibodies induce less vascular leak without loss of cytotoxicity.
Liu XY; Pop LM; Schindler J; Vitetta ES
MAbs; 2012; 4(1):57-68. PubMed ID: 22327430
[TBL] [Abstract][Full Text] [Related]
9. Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome.
Baluna R; Rizo J; Gordon BE; Ghetie V; Vitetta ES
Proc Natl Acad Sci U S A; 1999 Mar; 96(7):3957-62. PubMed ID: 10097145
[TBL] [Abstract][Full Text] [Related]
10. Anti-cancer activity of anti-p185HER-2 ricin A chain immunotoxin on gastric cancer cells.
Zhou XX; Ji F; Zhao JL; Cheng LF; Xu CF
J Gastroenterol Hepatol; 2010 Jul; 25(7):1266-75. PubMed ID: 20594254
[TBL] [Abstract][Full Text] [Related]
11. Delivery of saporin to human B-cell lymphoma using bispecific antibody: targeting via CD22 but not CD19, CD37, or immunoglobulin results in efficient killing.
Bonardi MA; French RR; Amlot P; Gromo G; Modena D; Glennie MJ
Cancer Res; 1993 Jul; 53(13):3015-21. PubMed ID: 7686448
[TBL] [Abstract][Full Text] [Related]
12. The activity of two immunotoxins composed of monoclonal antibody MoAb-16 and A-chain of ricin (MoAb-16-RTA) or A-chain of mistletoe lectin I (MoAb-16-MLIA).
Paprocka M; Wiedłocha A; Walzel H; Radzikowski C
Arch Immunol Ther Exp (Warsz); 1992; 40(3-4):223-7. PubMed ID: 1300987
[TBL] [Abstract][Full Text] [Related]
13. Highly potent CD22-recombinant ricin A results in complete cure of disseminated malignant B-cell xenografts in SCID mice but fails to cure solid xenografts in nude mice.
Van Horssen PJ; Preijers FW; Van Oosterhout YV; De Witte T
Int J Cancer; 1996 Nov; 68(3):378-83. PubMed ID: 8903481
[TBL] [Abstract][Full Text] [Related]
14. The in vivo anti-tumor activity of immunotoxins containing two versus one deglycosylated ricin A chains.
Ghetie V; Engert A; Schnell R; Vitetta ES
Cancer Lett; 1995 Nov; 98(1):97-101. PubMed ID: 8529213
[TBL] [Abstract][Full Text] [Related]
15. Increased sophistication of immunotoxins.
Frankel AE
Clin Cancer Res; 2002 Apr; 8(4):942-4. PubMed ID: 11948097
[No Abstract] [Full Text] [Related]
16. Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2.
Xu F; Leadon SA; Yu Y; Boyer CM; O'Briant K; Ward K; McWatters A; Zhao X; Bae DS; DeSombre K; Zalutsky MR; Bast RC
Clin Cancer Res; 2000 Aug; 6(8):3334-41. PubMed ID: 10955821
[TBL] [Abstract][Full Text] [Related]
17. A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma.
Messmann RA; Vitetta ES; Headlee D; Senderowicz AM; Figg WD; Schindler J; Michiel DF; Creekmore S; Steinberg SM; Kohler D; Jaffe ES; Stetler-Stevenson M; Chen H; Ghetie V; Sausville EA
Clin Cancer Res; 2000 Apr; 6(4):1302-13. PubMed ID: 10778955
[TBL] [Abstract][Full Text] [Related]
18. Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors.
Mansfield E; Amlot P; Pastan I; FitzGerald DJ
Blood; 1997 Sep; 90(5):2020-6. PubMed ID: 9292538
[TBL] [Abstract][Full Text] [Related]
19. A bispecific recombinant immunotoxin, DT2219, targeting human CD19 and CD22 receptors in a mouse xenograft model of B-cell leukemia/lymphoma.
Vallera DA; Todhunter DA; Kuroki DW; Shu Y; Sicheneder A; Chen H
Clin Cancer Res; 2005 May; 11(10):3879-88. PubMed ID: 15897589
[TBL] [Abstract][Full Text] [Related]
20. An immunotoxin prepared with blocked ricin: a natural plant toxin adapted for therapeutic use.
Lambert JM; Goldmacher VS; Collinson AR; Nadler LM; Blättler WA
Cancer Res; 1991 Dec; 51(23 Pt 1):6236-42. PubMed ID: 1718599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
